

CUMULATIVE INDEX

Psychopharmacology Bulletin

A. Contents Index

Vol. 22, No. 1—Annual NCDEU Meeting (1985)—Abridged Proceedings

- 3** The ECDEU-NCDEU Program—*Jonathan O. Cole*

- Re-Updates: New Perspectives on Long-Standing Issues—

- 7** Problems With and Promises of Monoamine Oxidase Inhibitors—*Donald F. Klein and Frederic M. Quitkin*
- 12** New Perspectives on Long-Standing Issues: The Monoamine Oxidase Inhibitors—*Donald S. Robinson*
- 16** Discussion on the Monoamine Oxidase Inhibitors—*Burtrum C. Schiele*
- 19** Use of Placebo in Clinical Trials—*Karl Rickels*
- 25** Scientific and Ethical Considerations in the Use of Placebo Controls in Clinical Trials in Psychopharmacology—*Gerald L. Klerman*
- 30** The Placebo Control in Clinical Trials (A View From the FDA)—*Paul Leber*
- 33** Pharmacological Treatments of Schizophrenia—*George M. Simpson*
- 36** Research Methodology and the Pharmacotherapy of the Chronic Schizophrenias—*Thomas A. Ban, William Guy, and W.H. Wilson*
- 42** Discussion of Dr. George Simpson's Paper on Pharmacological Treatments of Schizophrenia—*Solomon C. Goldberg*

- Multicenter International Clinical Trials—

- 45** Introduction—*Thomas A. Ban and Jerome Levine*

- 47** The AMDP System in International Clinical Trials—*B. Woggon, M. Linden, H. Beckmann, E. Krebs, B. Köfferle, B. Müller-Oerlinghausen, B. Pflug, and H.W. Schied*
- 52** Use of a Standardized Documentation System (BLIPS/BDP) in the Conduct of a Multicenter International Trial Comparing Fluvoxamine, Imipramine, and Placebo—*Giovanni B. Cassano, Luciano Conti, Gabriele Massimetti, Francesco Mengali, Jenifer S. Waekelin, and Jerome Levine*
- 59** The Design and Conduct of the Upjohn Cross-National Collaborative Panic Study—*Gerald L. Klerman, James H. Coleman, and Robert P. Purpura*

- Microcomputers in Clinical Psychopharmacology

- 65** Why a Statistical Package on a Micro?—*MaryAnn Hill*
- 73** Microcomputerized Testing of Drug Effects on Divided Attention—*Joe E. Thornton, Joy L. Taylor, Elizabeth L. Gibson, Terry P. Miller, and Jared R. Tinklenberg*

- Benzodiazepines—New Indications—

- 77** The Use of Benzodiazepines for Psychotic Disorders: A Literature Review and Preliminary Clinical Findings—*George W. Arana, Marjorie L. Ornstein, Fred Kanter, H.L. Friedman, David J. Greenblatt, and Richard I. Shader*
- 88** New Strategies for the Treatment of Alcohol Withdrawal—*E.M. Sellers and C.A. Naranjo*
- 93** Benzodiazepines for Treatment of Panic Attacks: A New Look—*Karl Rickels and Edward E. Schweizer*

Cholinergic Mechanisms in the Treatment of Geriatric Disorders—

- 101** Physostigmine in Patients With Alzheimer's Disease—*Michael Davidson, Richard C. Mohs, Eric Hollander, Bonnie M. Davis, Theresa Ryan, Thomas B. Horvath, and Kenneth L. Davis*
- 106** Intracranial Drug Administration in Alzheimer's Disease—*Robert E. Harbaugh*
- 110** The Cholinergic Hypothesis of Memory Dysfunction in Alzheimer's Disease—Revisited—*Nunzio Pomara and Michael Stanley*

Cholecystokinin: A Neuropeptide in the Treatment of Schizophrenia—

- 119** Ceruletide for Schizophrenia: A Review—*Jeffrey A. Mattes, William Hom, and Joseph M. Rochford*
- 123** Clinical Evaluation of Ceruletide in Schizophrenia: A Multi-Institutional Cooperative Double-Blind Controlled Study—*Hitoshi Itoh, Yasuo Shimazono, Yukio Kawakita, Yoshio Kudo, Yorio Satoh, and Ryo Takahashi*
- 129** Cholecystokinin: A Neuropeptide in the Treatment of Schizophrenia—*Carol A. Tamminga, Robert L. Littman, and Larry D. Alphs*

Fenfluramine Therapy for Autism: Promise and Precaution—

- 133** Fenfluramine Treatment of Autism: UCLA Collaborative Study of 81 Patients at Nine Medical Centers—*Edward R. Ritvo, B.J. Freeman, Arthur Yuwiler, Edward Geller, Phillip Schroth, Alice Yokota, Anne Mason-Brothers, Gerald J. August, William Klykko, Bennett Leventhal, Kay Lewis, Leonard Piggott, George Realmuto, E. Gene Stubbs, and Richard Umansky*
- 141** Short-Term Efficacy and Safety of Fenfluramine in Hospitalized Preschool-Age Autistic Children: An Open Study—*Magda Campbell, Stephen I. Deutsch, Richard Perry, Barbara B. Wolsky, and Michael Palij*

- 148** Fenfluramine: Neurotoxicity—*Charles R. Schuster, Marilyn Lewis, and Lewis S. Seiden*

- 152** Fenfluramine Treatment of Childhood Attention Deficit Disorder With Hyperactivity: A Preliminary Report—*Maureen Donnelly, Judith L. Rapoport, and Deborah R. Ismond*

- 155** The Effects of Fenfluramine on Suicidal Behavior—*Elaine Meyendorff, Anil Jain, Lil Träskman-Bendz, Barbara Stanley, and Michael Stanley*

Free Communications—Session A—

- 161** The Relationship of Antiobsessional and Antidepressant Effects of Tricyclic Antidepressants—*Matig Mavissakalian, Samuel M. Turner, Larry Michelson, and Rolf Jacob*
- 167** A Comparison of Alprazolam and Imipramine in the Treatment of Agoraphobia and Panic Disorder—*Ross Rizley, Richard J. Kahn, Douglas M. McNair, and Laura M. Frankenthaler*
- 173** Taper Withdrawal Studies With Alprazolam in Patients With Panic Disorder and Agoraphobia—*John C. Pecknold and Richard P. Swinson*
- 177** Amitriptyline and Haloperidol in Unstable and Schizotypal Borderline Disorders—*Paul H. Soloff, Anselm George, Swami Nathan, Patricia M. Schulz, Richard F. Ulrich, and James M. Perel*
- 183** Open Trial of Buspirone in the Treatment of Major Depressive Disorder—*Edward E. Schweizer, Jay Amsterdam, Karl Rickels, Myron Kaplan, and Marian Droba*
- 186** A Review of Controlled Studies of Adinazolam Mesylate in Patients With Major Depressive Disorder—*John P. Feighner*
- 192** Chronic Depression: Demographic and Clinical Characteristics—*James H. Kocsis, Carlyle Voss, J. John Mann, and Allen Frances*

- 196** Self-Rating of Personality Characteristics and Their Relationship to Treatment Response in Recurrent Unipolar Depressives: A Pilot Study—*Ellen Frank, David J. Kupfer, David B. Jarrett, and Miriam Jacob*
- 200** The Suicide Assessment Scale: A Scale Evaluating Change in Suicidal Behavior—*Barbara Stanley, Lil Träskman-Bendz, and Michael Stanley*
- 206** A Retrospective Clinical Analysis of the Overall-Rhoades Classification of Hamilton Depression Scale Profiles—*Robert H. Lenox, Lelon A. Weaver, James E. Shipley, and Stephen Cohen*
- 214** Understanding the Response Lag to Tricyclics: I. Application of Pulse-Loading Regimens With Intravenous Clomipramine—*Bruce G. Pollock, James M. Perel, Michael Shostak, Seymour Antelman, Barbara Bandom, and David J. Kupfer*
- 220** Pharmacology of Combined Antidepressant/ H_2 -Blocking Drug Therapy—*Stephen H. Curry, C. Lindsay DeVane, and M. Michael Wolfe*
- Free Communications—Session B—**
- 223** Methylphenidate: Rate-Dependent Effects on Hyperactivity—*Mark D. Rapport and George J. DuPaul*
- 229** The Therapeutic Effect of Clonidine in Attention Deficit Disorder with Hyperactivity: A Comparison With Placebo and Methylphenidate—*Robert D. Hunt, Ruud B. Minderaa, and Donald J. Cohen*
- 237** The Use of MK-801, A Novel Sympathomimetic, in Adults With Attention Deficit Disorder, Residual Type—*Fred W. Reimherr, David R. Wood, and Paul H. Wender*
- 243** The Prevalence of Tardive Dyskinesia in a Mentally Retarded Population—*Mary Ann Richardson, Gary Haugland, Raymond Pass, and Thomas J. Craig*
- 250** Neuroleptic-Induced Tardive Dyskinesia and Parkinsonism: Changes During Several Years of Continuing Treatment—*Daniel E. Casey, Uffe J. Povlsen, Birgit Meidahl, and Jes Gerlach*
- 254** Integrating Incidence and Prevalence of Tardive Dyskinesia—*John M. Kane, Margaret Woerner, Michael Borenstein, James Wegner, and Jeffrey Lieberman*
- 259** A Five-Year Follow-Up Study of Tardive Dyskinesia—*Guy Chouinard, Lawrence Annable, Pierre Mercier, and Andree Ross-Chouinard*
- 264** Plasma Fluphenazine Levels in Patients Receiving Two Doses of Fluphenazine Decanoate—*Stephen R. Marder, John W. Hubbard, Theodore Van Putten, Edward M. Hawes, Gordon McKay, Jim Mintz, Philip R.A. May, and Kamal K. Midha*
- 267** An Early Phase II Clinical Trial of Remoxipride in Schizophrenia With Measurement of Plasma Neuroleptic Activity—*Guy Chouinard and L. Turnier*
- 272** Measuring Adverse Drug Reactions in a Postmarketing Surveillance System—*Seymour Fisher, Stephen G. Bryant, and Ronica M. Kluge*
- 278** Estazolam in the Treatment of Insomnia—*Roberto A. Dominguez, Burton J. Goldstein, Alan F. Jacobson, and Richard M. Steinbook*
- NCDEU Workshop/Microcomputer Interest Group—**
- 281** Microcomputer Database Management Systems Concepts—*David Robert Gastfriend*
- 287** SAFTEE: Data System for Side-Effect Assessment Scale—*Dean J. Clyde*
- 288** Microprocessor-Based Assessment of Attention Deficit Disorders (ADD)—*Michael Gordon*
- 291** A Microcomputer-Based Psychophysiology Data Acquisition and Analysis System—*C. Keith Conners, Roy Clymer, and Robert S. Sherrick*

- 297** A Brain Function Diagnostic and Study Unit for Psychotropic Drug Development and Psychopharmacology Research—*Turan M. Itil, Donald M. Shapiro, Emin Eralp, Ahmet Akman, and Kurt Z. Itil*
- 301** BMDPC: BMDP Statistical Software for Microcomputers—*MaryAnn Hill*
- 307** Communications: Microcomputer/Mainframe Interfacing—*Pierre Mercier*
- 311** Expert Systems in Psychiatry—*Michael Feinberg and Robert K. Lindsay*
- 317** Cumulative Index—Psychopharmacology Bulletin—1985—
Contents Index
Authors Index
- B-1** Psychopharmacology—A Recurring Bibliography—

Vol. 22, No. 2—1986

Report of the NIMH-NIH Consensus Development Conference on Electroconvulsive Therapy—

- 445 Introduction—*Jack Blaine and Susan M. Clark*

Statement of the Consensus Development Panel

Abstracts of Presentations to the Panel and Conference—

- 455 The Use of Somatic Treatments for Psychiatric Illnesses—*Gerald L. Klerman*
- 457 Convulsive Therapy: How It Evolved—*Max Fink*
- 459 ECT: The Historical, Social, and Professional Sources of the Controversy—*David J. Rothman*
- 463 Utilization of ECT in U.S. Psychiatric Facilities, 1975 to 1980—*James W. Thompson*
- 465 Efficacy in Depression: Controlled Trials—*Sydney Brandon*
- 468 Efficacy in Depression: ECT Versus Anti-depressants—*Jan Fawcett and William Scheftner*
- 469 Efficacy of ECT in Schizophrenia, Mania, and Other Disorders—*Joyce G. Small*
- 472 ECT: Possible Mechanisms of Action—*Bernard Lerer*
- 475 Systemic Effects of ECT—*Trevor R.P. Price*
- 476 Neuropathology and Cognitive Dysfunction from ECT—*Peter R. Breggin*
- 479 Quantitative Neuropathology in Electrically Induced Generalized Convulsions—*Agnete M. Dam*
- 482 Acute Cognitive Side Effects of ECT—*Harold A. Sackeim*
- 484 The Question of Long-Term Effects—*Larry R. Squire*
- 487 Patients' Attitudes Toward ECT—*Christopher Freeman*
- 339 **In the Pipeline—George M. Simpson**
Strategies for Analyzing Side Effect Data from SAFTEE—
- 343 SAFTEE: A Technique for the Systematic Assessment of Side Effects in Clinical Trials—*Jerome Levine and Nina R. Schooler*
- 382 Interrater Agreement and Intraclass Reliability Measures of SAFTEE in Psychopharmacologic Clinical Trials—*Alan F. Jacobson, Burton J. Goldstein, Roberto A. Dominguez, and Richard M. Steinbook*
- 389 Side Effect Assessment With SAFTEE: Pilot Study of the Instrument—*Judith Godwin Rabkin and Jeffrey S. Markowitz*
- 397 Reliability and Validity of SAFTEE: Preliminary Analyses—*William Guy, William H. Wilson, Beth Brooking, Gregory Manov, and Olaf Fjetland*
- 402 Side Effects Data Analysis—*Philip W. Lavori*
Issues in the Long-Term Use of Benzodiazepines Workshop—
- 405 Introduction—*Karl Rickels and Allen Raskin*
- 407 Low-Dose Dependence in Chronic Benzodiazepine Users: A Preliminary Report on 119 Patients—*Karl Rickels, W. George Case, Edward E. Schweizer, Charlotte Swenson, and Reita B. Fridman*
- 416 Long-Term Administration of Benzodiazepines: Pharmacokinetic versus Pharmacodynamic Tolerance—*David J. Greenblatt and Richard I. Shader*
- 424 The Behavioral Effects of Benzodiazepines Following Long-Term Use—*Irwin Lucki and Karl Rickels*
- 434 A Survey of Diazepam Patients—*David Haskell, Jonathan O. Cole, Susan Schniebolk, and Bernard Lieberman*
- 439 Physiological and Performance Responses to Diazepam: Two Types of Effects—*Rudolf Hoehn-Saric and Daniel R. McLeod*

- 490 Legal Parameters of Informed Consent for ECT Administered to Mentally Disabled Persons—*John Parry*
- 494 Data on Informed Consent for ECT—*Loren H. Roth*
- 495 Clinical Strategies in Choice and Timing of ECT—*Richard Abrams*
- 497 General Technique of ECT—*Ferris N. Pitts, Jr.*
- 499 Electrical Dosage, Stimulus Parameters, and Electrode Placement—*Richard D. Weiner*
- Articles—
- 503 Major Depression and Panic Disorder: Diagnostic and Neurobiological Relationships—*Dennis S. Charney, George R. Heninger, Lawrence H. Price, and Alan Breier*
- 512 The Role of the Locus Coeruleus—Limbic Noradrenergic Transmission in the Action of Antidepressant Drugs—*Wojciech Kostowski, Adam Plaznik, and Wojciech Danysz*
- 523 Eating Disorders: A Bibliography—*Natalie Reatig*
- 532 Attention Deficit Disorders: A Bibliography—*Natalie Reatig*
- 543 Psychobiological Markers for Schizophrenia: State of the Art and Future Perspectives—*Joseph Zubin* (Corrected and reprinted from Vol. 21, No. 3, 1985 of the *Bulletin*)
- B1 Psychopharmacology—A Recurring Bibliography—

Vol. 22, No. 3—24th Annual Meeting of the ACNP—Abridged Proceedings

24th Annual Meeting of the ACNP—1985—Abridged Proceedings—**Strategies for Advance in Maintenance Therapies**

- 553** Maintenance Phenelzine Treatment of Major Depression: An Interim Report—*Donald S. Robinson, Allen Kayser, Binni Bennett, Elizabeth Devereaux, Sidney C. Lerfald, Doris Albright, Desmond Laux, and John Corcella*

- 558** Psychotherapeutic Approaches to Treatment of Recurrent Unipolar Depression: Work in Progress—*Ellen Frank and David J. Kupfer*

Peripheral Hormones: A Window on the Central MA?—

- 565** The Pitfalls of Serotonin Precursors as Challengers in Hormonal Probes of Central Serotonin Activity—*Herman M. van Praag, Carmen Lemus, and Rene Kahn*

- 571** The Desipramine Cortisol Test—A Selective Noradrenergic Challenge (Relationship to Other Cortisol Tests in Depressives and Normals)—*Gregory M. Asnis, Carmen Z. Lemus, and Uriel Halbreich*

Etiological Theories of Depression: Experimental Paradigms in Animals—

- 579** A Developmental Perspective on Recurrent Mood Disorders: A Review of Studies in Man—*Hagop S. Akiskal*

- 587** Developmental Theories of Depression in Nonhuman Primates—*Gary W. Kraemer*

Biochemical and Functional Studies of D-1 Dopamine Receptors—

- 593** Multiple Forms of the D₁ Dopamine Receptor: Its Linkage to Adenylate

Cyclase and Psychopharmacological Effects—*Richard B. Mailman, David W. Schulz, Clinton D. Kilts, Mark H. Lewis, Hans Rollema, and Steven Wyrick*

- 599** Structural Analogs of SCH 23390 as Discriminators of Dopamine Receptor Subtypes: Behavioral Interactions Between D-1 and D-2 Agonists and Antagonists—*Kathy M. O'Boyle, Anthony G. Molloy, Marcellina Mashurano, and John L. Waddington*

- 605** Biochemical and Behavioral Studies of D₁ Dopamine Receptors Utilizing SCH23390—*Ellen J. Hess and Ian Creese*

Mixed Mania: Diagnosis and Treatment—

- 613** Sources of Lithium Resistance in Mixed Mania—*Jonathan M. Himmelhoch and Marc E. Garfinkel*

Expressed Emotion of Relatives, Maintenance Drug Treatment, and Relapse in Schizophrenia and Mania—

- 621** Expressed Emotion, Maintenance Pharmacotherapy, and Schizophrenic Relapse Among Mexican-Americans—*Janis H. Jenkins, Marvin Karno, Aurora de la Selva, Felipe Santana, Cynthia Telles, Steven Lopez, and Jim Mintz*

- 628** Expressed Emotion, Affective Style, Lithium Compliance, and Relapse in Recent Onset Mania—*David J. Miklowitz, Michael J. Goldstein, Keith H. Nuechterlein, Karen S. Snyder, and Jeri A. Doane*

- 633** Expressed Emotion, Fixed-Dose Fluphenazine Decanoate Maintenance, and Relapse in Recent-Onset Schizophrenia—*Keith H. Nuechterlein, Karen S. Snyder, Michael E. Dawson, Sandra*

Rappe, Michael Gitlin, and David Fogelson

The Benzodiazepine/GABA Receptor: From Molecular Structure to Function in Man—

- 641** Molecular Aspects of Benzodiazepine Receptor Function—*Paul Sweetnam, Peter Gallombardo, and John Tallman*
Neurochemical Correlates of Suicide—
- 647** Postmortem Serotonergic and Adren-
ergic Receptor Binding to Frontal
Cortex: Correlations With Suicide—
*J. John Mann, P. Anne McBride, and
Michael Stanley*
- 650** Suicide and Adrenocortical Func-
tion—*James H. Kocsis, Sara Kennedy,
Richard P. Brown, J. John Mann, and
Barbara Mason*
- 656** Suicidal Potential in Depression: Fo-
cus on CSF Monoamine and Purine
Metabolites—*Hans Ågren and Frank
Niklasson*
- 661** Monoamines, Glucose Metabolism, Su-
icidal and Aggressive Behaviors—*Alec
Roy, Matti Virkkunen, Sally Guthrie, Rus-
sell Poland, and Markku Linnoila*
- 666** Genetic Factors in Suicide—*Alec Roy*
- 669** (Auto)Aggression and CSF 5-HIAA in
Depression and Schizophrenia—
Herman M. van Praag
**Acquired Immunodeficiency Syn-
drome (AIDS): Neuropsychologic
and Psychoimmunologic Aspects—**
- 675** Introduction—*T. Peter Bridge and
Donald I. Macdonald*
- 678** Psychosocial Aspect of AIDS Risk—
*David G. Ostrow, Jill Joseph, Andrew
Monjan, Ronald Kessler, Carol Emmons,
John Phair, Robin Fox, Lawrence Kings-
ley, Janice Dudley, Joan S. Chmiel, and
Mark Van Raden*
- 684** Neuropsychiatric Aspects of AIDS—
*Russell T. Joffe, David R. Rubinow, Kath-
leen Squillace, Clifford H. Lane, Connie
C. Duncan, and Anthony S. Fauci*
- 689** Localization of the T4 Antigen/AIDS
Virus Receptor in Monkey and Rat
Brain: Prominence in Cortical Re-
gions—*Joanna M. Hill, William L. Far-
rar, and Candace B. Pert*
- 695** Methionine Enkephalin: Enhancement
of T-Cells in Patients With Kaposi's
Sarcoma (AIDS)—*N.P. Plotnikoff, J.
Wybran, N.F. Nimeh, and G.C. Miller*
**Molecular Biology: Relevance to
Neuropsychopharmacology and Psy-
chiatry—**
- 699** Introduction—*Samuel H. Barondes*
- 701** Identifying Neuropeptides by Gene
Cloning—*Floyd E. Bloom*
- 708** Use of Gene Transfer Techniques to
Study Neuropeptide Gene Regula-
tion—*Edward Herbert, Audrey F.
Seasholtz, and Michael Comb*
**Neuropsychopharmacology of Alco-
hol and Drug Abuse—**
- 717** Interactions of Alcohol and Drugs of
Abuse—*Monique C. Braude*
**Neuropharmacological Approaches
to the Obsessive-Compulsive Syn-
drome—**
- 723** Epidemiologic and Clinical Findings of
Significance to the Design of Neuro-
pharmacologic Studies of Obsessive-
Compulsive Disorder—*Steven A. Ras-
mussen and Ming T. Tsuang*
- 730** A Possible Genetic Relationship Exists
Between Tourette's Syndrome and
Obsessive-Compulsive Disorder—
*David L. Pauls, James F. Leckman, Ken-
neth E. Towbin, Gwendolyn Zahner, and
Donald J. Cohen*
**Problems and Promises of Post-
Mortem Brain Tissue Analysis—**
- 735** Role of the Serotonergic System in the
Postmortem Analysis of Suicide—
*Michael Stanley, J. John Mann, and Lee
S. Cohen*
- 741** Aminergic Receptor Binding Corre-
lates of Suicide: Methodological Is-

sues—*J. John Mann, P. Anne McBride, and Michael Stanley*

Appetite and Satiety Regulation: Pharmacological Strategies—

- 745** Neuropeptides as Stimulators of Feeding—*John E. Morley, James E. Mitchell, and Allen S. Levine*

Psychotoxic Manifestations in Amphetamine Abuse—

- 751** Acute Exacerbation of Methamphetamine Psychosis and Lasting Dopaminergic Supersensitivity—A Clinical Survey—*Mitsumoto Sato*
- 757** Reverse Tolerance to the Ambulation-Increasing Effect of Methamphetamine in Mice as an Animal Model of Amphetamine-Psychosis—*Sakutaro Tadokoro and Hisashi Kuribara*

- 763** Psychotic Manifestations in Amphetamine Abuse—Experimental Study on the Mechanism of Psychotic Recurrence—*Kiyoshi Ando, Naoyuki Hironaka, and Tomoji Yanagita*

- 768** Visual Perception Process in Amphetamine Psychosis and Schizophrenia—*Takuya Kojima, Eisuke Matsushima, Hisayuki Iwama, Harunobu Ando, Hirobumi Moriya, Katsumi Ando, Ryo Takahashi, and Yasuo Shimazono*

Membrane Lipids: From Signal Transduction to Neuropsychiatric Disease—

- 775** Changes in Receptor Stimulated Phosphoinositide Hydrolysis in Brain During Ethanol Administration, Aging, and Other Pathological Conditions—*Fulton T. Crews, Rueben A. Gonzales, Reinhard Palovcik, M. Ian Phillips, Cynthia Theiss, and Mohan Raizada*
- 781** "Autocannibalism" of Membrane Choline-Phospholipids: Physiology and Pathology—*Jan K. Blusztajn, Pamela G. Holbrook, Michael Lakher, Mordechai Liscovitch, Jean-Claude Maire, Charlotte Mauron, U. Ingrid Richardson, Mariateresa Tacconi, and Richard J. Wurtman*

Panic Disorder: Clinical Characteristics, Epidemiology, and Treatment—

- 787** The Relationship Between Panic Disorder and Agoraphobia: An Epidemiologic Perspective—*Myrna M. Weissman, Philip J. Leaf, Dan G. Blazer, Jeffrey H. Boyd, and Louis Florio*

- 792** Recent Developments in the Understanding and Pharmacotherapy of Panic Attacks—*Michael R. Liebowitz, Abby J. Fyer, Jack Gorman, and Donald F. Klein*

- 797** Possible Respiratory Abnormalities in Panic Disorder—*Jack M. Gorman, Michael R. Liebowitz, Abby J. Fyer, Minna R. Fyer, and Donald F. Klein*

- 802** Behavioral Conception and Treatment of Panic—*David H. Barlow*

Etiology and Treatment: Basic and Clinical Neuroscience Investigations—

- 807** Nonbenzodiazepine Anxiolytics: Insights Into Possible Mechanisms of Action—*Cam P. VanderMaelen, Duncan P. Taylor, Greta Gehlbach, and Michael S. Eison*

Serotonin Receptor Subtypes: Biochemical, Physiological, Behavioral, and Clinical Implications—

- 813** Analysis of 5-HT₁ Binding Site Subtypes and Potential Functional Correlates—*Stephen J. Peroutka, Richard E. Heuring, Michael D. Mauk, and Jeffery D. Kocsis*
- 818** Labeling of the 5-HT_{1A} Receptor Subtype—*Jean C. Shih, Kenneth B. Asarch, and Richard Ransom*
- 825** Substituted Phenylpiperazines as Serotonin Agonists: Structural Determinants of Potency and Interaction With Receptor Subtypes—*Ray W. Fuller*
- 829** Effector Systems Coupled to Serotonin Receptors in Brain: Serotonin Stimulated Phosphoinositide Hydrolysis—*Elaine Sanders-Bush and P. Jeffrey Conn*

- 837** Serotonin Receptor Subtype Agonists: Differential Effects on Sensorimotor Reactivity Measured With Acoustic Startle—*Michael Davis, James V. Cassella, William H. Wren, and John H. Kehne*

Influences of Pharmacologic and Psychosocial Factors on the Course of Schizophrenia—

- 845** Prediction of Relapse in Schizophrenia—*Jeffrey A. Lieberman, John M. Kane, Stavros Sarantakos, Dominick Gadaletta, Margaret Woerner, Jose Alvir, and Jorge Ramos-Lorenzi*
- 854** Interpersonal and Pharmacologic Treatment in Schizophrenia: A Comparative Study of New Approaches—*William T. Carpenter, Jr., Douglas W. Heinrichs, and Thomas E. Hanlon*
- 860** Medication, Family Psychoeducation, and Social Skills Training: First Year Relapse Results of a Controlled Study—*Gerard E. Hogarty and Carol M. Anderson*

Nicotine as a Psychoactive Drug: Anxiety and Pain Reduction, Arousal, and Appetite Regulation—

- 863** Introduction—*Ovide F. Pomerleau*
- 865** Nicotine as a Psychoactive Drug: Anxiety and Pain Reduction—*Ovide F. Pomerleau*
- 870** Nicotine: A Unique Psychoactive Drug—Arousal With Skeletal Muscle Relaxation—*Edward F. Domino*
- 875** Nicotine as a Psychoactive Drug: Appetite Regulation—*Neil E. Grunberg*
- 882** Nicotine as a Psychoactive Drug—Panel Summary—*Murray E. Jarvik*

Basic and Clinical Aspects of Prefrontal Cortex Physiology in Neuropsychiatry—

- 885** Electrophysiological Evidence Implicating Frontal Lobe Dysfunction in Schizophrenia—*John M. Morihisa*

Neuroleptic-Induced Psychological Supersensitivity Syndromes: Are These Syndromes Myth or Reality?—

- 891** Supersensitivity Psychosis and Tardive Dyskinesia: A Survey in Schizophrenic Outpatients—*Guy Chouinard, Lawrence Annable, and Andree Ross-Chouinard*
- 897** Associations Among Plasma Prolactin Levels, Tardive Dyskinesia, and Paranoia in Treated Schizophrenics: Relevance to Supersensitivity Psychosis—*John G. Csernansky, Sophia Vinogradov, Elisabeth Prosser, Jonathan Kaplan, Philip A. Berger, and Leo E. Hollister*
- 900** Basic and Clinical Studies of Neuroleptic-Induced Supersensitivity Psychosis and Dyskinesia—*Bruce I. Diamond and Richard L. Borison*

Recent Advances in HPA Physiology and Pathophysiology (II)—

- 907** Corticotropin-Releasing Hormone—A New Tool to Investigate Hypothalamic-Pituitary-Adrenocortical Physiology in Psychiatric Patients—*Florian Holsboer*
- 913** Multiendocrine Assessment in the Dexamethasone Suppression Test—*S. Craig Risch, David S. Janowsky, Lewis L. Judd, Christian Gillin, Mariam Mott, Jeffrey L. Rausch, and Leighton Y. Huey*

Recent Advances in Biomedical Research in Schizophrenia—

- 917** Introduction—*Robert O. Friedel*
- 918** The Genetics of Schizophrenia: A Current Perspective—*Kenneth S. Kendler*
- 923** The Dopamine Hypothesis: Variations on a Theme (II)—*Richard Jed Wyatt*
- 928** The Combined Use of Neuroleptics and ECT in Drug Resistant Schizophrenic Patients—*Robert O. Friedel*

Psychotropic Drug Receptors and Brain Function: Molecular Bases to Clinical Implications (CINP/ACNP)—

- 931** Lack of Serotonergic Modulation on ³H-Imipramine Binding Sites in Basal Conditions and During Prolonged Treatment With Desmethylinipramine—*Nicoletta Brunello, Alessandra Cecilia Rovescalli, Marco Riva, and Giorgio Racagni*

Drug Washout Effects on Clinical Studies in Depression and Schizophrenia—

- 937** Effects of Drug Washout on CSF Monoamine and Psychoendocrine Variables—*Hans Ågren and William Z. Potter*

Brain Norepinephrine and Stress: A Vertical Synthesis—

- 943** Behavioral Depression Following Clonidine Withdrawal: A New Animal Model of Long-Lasting Depression?—*Laura J. Hoffman and Jay M. Weiss*

Mechanisms of Action of Indole and Phenylalkylamine Hallucinogens—

- 951** Introduction—*Richard H. Rech*
- 953** Structure-Activity Relationships and Mechanism of Action of Hallucinogenic Agents Based on Drug Discrimination and Radioligand Binding Studies—*Richard A. Glennon, Milt Titeler, and Richard Young*
- 959** The Use of Drug Discrimination Procedures to Characterize Hallucinogenic Drug Actions—*James B. Appel and Kathryn A. Cunningham*
- 968** Disruption of Operant Behavior by Hallucinogenic Drugs—*Richard H. Rech and David J. Mokler*
- 973** Comparison of Phencyclidine and Related Substances With Various Indole, Phenethylamine, and Other Psychotomimetics—*Edward F. Domino*

- 977** Clinical Aspects of Use of Phenylalkylamine and Indolealkylamine Hallucinogens—*Leo E. Hollister*

The "Pros" and "Cons" of Anticholinergic Prophylaxis—

- 981** Anticholinergic Prophylaxis in Young Adults Treated With Neuroleptic Drugs—*C. Raymond Lake, Daniel E. Casey, Joseph P. McEvoy, Samuel G. Siris, William F. Boyer, and George Simpson*

Poster Sessions—Editors' Choice

- 985** The Inventory of Depressive Symptomatology: Preliminary Findings—*A. John Rush, Donna E. Giles, Michael A. Schlesser, Carl L. Fulton, Jan Weisenburger, and Cheryl Burns*
- 991** Chronic Lithium and Desmethylinipramine Modulation of Locomotor Response to Growth Hormone Releasing Factor—*Cindy L. Ehlers, Alfred Lopez, and R. Ian Chaplin*
- 995** Postmarketing Surveillance of Long-Term Amitriptyline Side Effects—*Stephen G. Bryant, Seymour Fisher, and Ronica M. Kluge*
- 999** The Patient, the Family, and Compliance With Posthospital Treatment for Affective Disorders—*Gretchen L. Haas, Ira D. Glick, James H. Spencer, John F. Clarkin, Alfred B. Lewis, Marcie Good-Ellis, Joanne Peyser, Nancy DeMane, Elizabeth Harris, and Veronica Lestelle*
- 1006** The Antipsychotic Drug Haloperidol Decreases Basal Ganglia Substance P, Substance K, and Preprotachykinin mRNAs—*Michael J. Bannon, Jin-Moo Lee, Pierre Giraud, Alice Young, Hans-Urs Affolter, and Tom I. Bonner*
- 1011** Alpha-2 Adrenergic Agonist Binding in Schizophrenic Brains—*Grant N. Ko, James R. Unnerstall, Michael J. Kuhar, Richard J. Wyatt, and Joel E. Kleinman*
- 1017** Dose-Dependent Increases in Rat Spontaneous Chewing Rates During

- Long-Term Administration of Haloperidol but Not Clozapine—*Per Johansson, Daniel E. Casey, and Lars M. Gunne*
- 1020** Identification and Testing of New Drugs for Modulating Alcohol Consumption—*Mary O. Lawrin, Claudio A. Naranjo, and Edward M. Sellers*
- 1026** Effects of Noon Meals, Varying in Nutrient Composition, on Plasma Amino Acids, Glucose, Insulin, and Behavior—*Bonnie Spring, June Chiodo, Margarette Harden, Michael Bourgeois, Lorenz Lutherer, Debra Harner, Sherry Crowell, and Geoffrey Swope*
- 1030** Mouse Strain Differences in Acquisition of Discrete Lever-Press and Shuttle Avoidance Responses, and Drug Effects Thereon—*Hisashi Kuribara and Sakutaro Tadokoro*
- 1036** Differential Erythropoietic Response to Oxiracetam in Alzheimer's Disease and Multi-Infarct Dementia: A Potential Biological Marker—*Roland J. Branconnier, Eric C. Dessain, Maureen E. McNiff, Nancy E. Harto, Karen F. Spera, Richard Katz, Frank Stallone, Joseph DeVeauugh-Geiss, and Jonathan O. Cole*
- 1040** Thioridazine Metabolism and Effects on Stereotyped Behavior in Mentally Retarded Patients—*Mark H. Lewis, Robert A. Steer, Judith Favell, James McGimsey, Luther Clontz, Carole Trivette, Wendy Jodry, Stephen R. Schroeder, Robert C. Kanoy, and Richard B. Mailman*

Vol. 22, No. 4

Methodological Issues in Treatment Research of Mental Illness in the Mentally Retarded—

- 1045** Introduction—*Shervert Frazier*
- 1046** Overview of Research in Psychopharmacological Treatment of the Mentally Ill/Mentally Retarded—*Ronald S. Lipman*
- 1055** Limiting Factors in the Use of *DSM-III* Criteria With Mentally Ill/Mentally Retarded Persons—*Robert Sovner*
- 1060** The Nature and Types of Mental Illness in the Mentally Retarded—*Frank J. Menolascino, Andrew Levitas, and Carl Greiner*
- 1072** Psychometric and Demographic Characteristics of the Psychopathology Instrument for Mentally Retarded Adults—*Michael G. Aman, Janine E. Watson, Nirbhay N. Singh, Sarah H. Turbott, and Catherine P. Wilsher*
- 1077** Components of the Design of Psychopharmacology Studies—*Barbara Geller*
- 1081** Treatment Outcome Research for Depression in Mentally Retarded Children and Youth: Methodological Issues—*Johnny L. Matson*
- 1086** Summary: Challenges for Research—*Eleanor D. Dibble*

Neuropeptides and Psychoneuroimmunology—

- 1089** Neuropeptides as Modulators of Immune Function—*John E. Morley and Neil Kay*
- 1093** Life Events, Depression, and Natural Killer Cell Activity—*Michael Irwin, Marcia Daniels, Eda T. Bloom, and Herbert Weiner*
- 1097** Methionine Enkephalin: Immunomodulator in Normal Volunteers (*in Vivo*)—*Nicholas P. Plotnikoff, Gerald C. Miller, Suman K. T. Solomon, Robert E. Faith, Larry D. Edwards, and Anthony J. Murgio*

The Forum—

- 1101** Issues in the Diagnosis of Attention Deficit Disorder: A Cautionary Note on the Gordon Diagnostic System—*Richard Milich, William E. Pelham, and Stephen P. Hinshaw*

B1 Psychopharmacology—A Recurring Bibliography—

